Absci (ABSI) Total Non-Current Liabilities (2020 - 2026)
Absci's (ABSI) quarterly Total Non-Current Liabilities came in at $22.8 million in Q1 2026, down 28.62% year-on-year from $32.0 million in Q1 2025, and down 11.65% quarter-over-quarter from $25.8 million in Q4 2025.
Absci (ABSI) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Absci has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $22.8 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $22.8 million, down 28.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.8 million (down 28.62% YoY), and the FY2025 annual result was $25.8 million, down 24.8% from the prior year.
- Total Non-Current Liabilities came in at $22.8 million for Q1 2026 at Absci, down from $25.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $54.7 million in Q1 2022 to a low of $22.8 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $35.0 million (2025), against an average of $37.9 million.
- Across the five-year window, Total Non-Current Liabilities sank 75.66% in 2022 and climbed 2.97% in 2025, its largest moves.
- Absci's Total Non-Current Liabilities stood at $46.6 million in 2022, then decreased by 12.31% to $40.8 million in 2023, then dropped by 15.88% to $34.3 million in 2024, then fell by 24.8% to $25.8 million in 2025, then fell by 11.65% to $22.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $22.8 million (Q1 2026), $25.8 million (Q4 2025), and $32.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | 22.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.82 Mn |
| Dec 31, 2025 | 25.83 Mn |
| Sep 30, 2025 | 32.87 Mn |
| Jun 30, 2025 | 35.04 Mn |
| Mar 31, 2025 | 31.97 Mn |
| Dec 31, 2024 | 34.34 Mn |
| Sep 30, 2024 | 33.87 Mn |
| Jun 30, 2024 | 34.03 Mn |
| Mar 31, 2024 | 34.71 Mn |
| Dec 31, 2023 | 40.83 Mn |
| Sep 30, 2023 | 39.93 Mn |
| Jun 30, 2023 | 38.75 Mn |
| Mar 31, 2023 | 41.84 Mn |
| Dec 31, 2022 | 46.56 Mn |
| Sep 30, 2022 | 46.41 Mn |
| Jun 30, 2022 | 49.90 Mn |
| Mar 31, 2022 | 54.74 Mn |
| Dec 31, 2021 | 47.93 Mn |
| Sep 30, 2021 | 48.98 Mn |
| Jun 30, 2021 | 204.96 Mn |